Unity Biotechnology Inc Expected To Post A Loss Of 53 Cents A Share: Earnings Preview

Unity Biotechnology

03/05/2024 13:04

* UNITY Biotechnology Inc  UBX.OQ   UBX.O  is expected
to show no
change in quarterly revenue when it reports  results on May 7
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for UNITY Biotechnology Inc
is for
a loss of 53 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $6.00​, above​ its last closing price
of $1.63. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.62       -0.72      -0.28     Beat    61.2
 Sep. 30 2023  -0.99       -0.96      -0.66     Beat    31.4
 Jun. 30 2023  -0.83       -0.86      -0.85     Beat    0.7​
 Mar. 31 2023  -1.08       -1.08      -0.76     Beat    29.9
 ​​Jan.        -1.01       -1.05      -1.00     Beat    4.6
 1 0001                                                 
 Sep. 30 2022  -1.62       -1.65      -1.36     Beat    17.4​
 Jun. 30 2022  -2.70       -2.80      -1.90     Beat    32.1
 Mar. 31 2022  -2.52       -2.57      -2.80     Missed  -8.8
 This summary was machine generated May 3 at 12:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)